Browsing by Author "Kalergis Parra, Alexis Mikes"

Now showing 1 - 20 of 339
  • Thumbnail Image
    Item
    A Herpes Simplex Virus Type 2 Deleted for Glycoprotein D Enables Dendritic Cells to Activate CD4(+) and CD8(+) T Cells
    (2017) Retamal Díaz, Angello Ricardo; Kalergis Parra, Alexis Mikes; Bueno Ramírez, Susan; González, P.
  • Thumbnail Image
    Item
    A Novel Live Vector Group A Streptococcal emm Type 9 Vaccine Delivered Intranasally Protects Mice against Challenge Infection with emm Type 9 Group A Streptococci
    (2014) Wozniak Banchero, Aniela; García Cañete, Patricia; Geoffroy, Enrique A.; Aguirre, Daniel B.; González, Samantha; Sarno, Victoria A.; Dale, James B.; Salazar Echegarai, Francisco Javier; Vera, Andrea Magdalena; Bueno Ramírez, Susan; Kalergis Parra, Alexis Mikes
  • Thumbnail Image
    Item
    A potential role of Salmonella infection in the onset of inflammatory bowel diseases
    (2017) Schultz, B.; Paduro, C.; Salazar, G.; Salazar Echegarai, F.; Sebastián Quijada, Valentina Pilar; Riedel, C.; Kalergis Parra, Alexis Mikes; Álvarez Lobos, M.; Bueno Ramírez, Susan
  • Thumbnail Image
    Item
    A safe and efficient BCG vectored vaccine to prevent the disease caused by the human Respiratory Syncytial Virus
    (2017) Rey Jurado, Emma; Soto, Jorge; Galvez, Nicolás; Kalergis Parra, Alexis Mikes
  • Thumbnail Image
    Item
  • Thumbnail Image
    Item
    A single, low dose of a cGMP recombinant BCG vaccine elicits protective T cell immunity against the human respiratory syncytial virus infection and prevents lung pathology in mice
    (2017) Céspedes, Pablo F.; Rey-Jurado, Emma; Espinoza Véliz, Janyra Alejandra; Rivera, Claudia A.; Canedo Marroquín, Gisela Eliana; Bueno Ramírez, Susan; Kalergis Parra, Alexis Mikes
  • Thumbnail Image
    Item
    Aberrant T cell immunity triggered by human Respiratory Syncytial Virus and human Metapneumovirus infection
    (2017) González, A. E.; Lay, M. K.; Jara, E. L.; Espinoza, J. A.; Gómez, R. S.; Soto, J.; Rivera, C. A.; Abarca Villaseca, Katia; Bueno Ramírez, Susan; Riedel, C. A.; Kalergis Parra, Alexis Mikes
  • Thumbnail Image
    Item
    Activated TCRs remain marked for internalization after dissociation from pMCH
    (2002) Coombs, D.; Kalergis Parra, Alexis Mikes
  • Thumbnail Image
    Item
    Activating and inhibitory Fc gamma receptors can differentially modulate T cell-mediated autoimmunity
    (2008) Iruretagoyena B., Mirentxu; Riedel Soria, Claudia; Leiva Llantén, Eduardo David; Gutiérrez Torres, Miguel Alejandro; Jacobelli, Sergio H.; Kalergis Parra, Alexis Mikes
  • No Thumbnail Available
    Item
    Advances in understanding respiratory syncytial virus infection in airway epithelial cells and consequential effects on the immune response
    (2013) Bueno Ramírez, Susan Marcela; Cespedes Donoso, Pablo Francisco; González, Pablo A.; Kalergis Parra, Alexis Mikes; Lay Remolcoi, Margarita Kam-len; León, Miguel A.; Riedel Soria, Claudia
    This article reviews aspects of respiratory syncytial virus (RSV) infection in airway epithelial cells (AECs), including cytopathogenesis, entry, replication and the induction of immune response to the virus, including a new role for thymic stromal lymphopoietin in RSV immunopathology. (C) 2012 Institut Pasteur. Published by Elsevier Masson SAS. All rights reserved.
  • Thumbnail Image
    Item
    Age-Related Changes in 11 beta-Hydroxysteroid Dehydrogenase Type 2 Activity in Normotensive Subjects
    (2013) Campino Johnson, María del Carmen; Martínez Aguayo, Alejandro Gregorio; Baudrand Biggs, René; Carvajal Maldonado, Cristián Andrés; Aglony Imbarack, Marlene Elizabeth; García Bruce, Hernán; Padilla Pérez, Oslando; Kalergis Parra, Alexis Mikes; Fardella B., Carlos
  • Thumbnail Image
    Item
    Aldosterona e IL-17 en la génesis de la hipertensión arterial mineralocorticoídea, un estudio ex vivo
    (2016) Vecchiola Cárdenas, Andrea Paola; Cristóbal Fuentes, Z.; Muñoz Durango, Natalia; Tapia Castillo, Alejandra; González Gómez, Luis M.; Baudrand Biggs, René; Carvajal Maldonado, Cristián Andrés; Campino Johnson, María del Carmen; Kalergis Parra, Alexis Mikes; Carlos, F.; Lagos, A.; Fardella B., Carlos; Vecchiola Cárdenas, Andrea Paola; Cristóbal Fuentes, Z.; Muñoz Durango, Natalia; Tapia Castillo, Alejandra; González Gómez, Luis M.; Baudrand Biggs, René; Carvajal Maldonado, Cristián Andrés; Campino Johnson, María del Carmen; Kalergis Parra, Alexis Mikes; Carlos, F.; Lagos, A.; Fardella B., Carlos
  • Thumbnail Image
    Item
    Aldosterone as a modulator of immunity: implications in the organ damage
    (2011) Herrada, A.; Campino Johnson, María del Carmen; Fardella B., Carlos; Kalergis Parra, Alexis Mikes
  • Thumbnail Image
    Item
    Allergens of the urushiol family promote mitochondrial dysfunction by inhibiting the electron transport at the level of cytochromes b and chemically modify cytochrome c1
    (2021) Pacheco, Rodrigo; Quezada, Sergio A.; Kalergis Parra, Alexis Mikes; Becker C., María Inés; Ferreira, Jorge; Ioannes, Alfredo E. de
    Background: Urushiols are pro-electrophilic haptens that cause severe contact dermatitis mediated by CD8+ effector T-cells and downregulated by CD4+ T-cells. However, the molecular mechanism by which urushiols stimulate innate immunity in the initial stages of this allergic reaction is poorly understood. Here we explore the sub-cellular mechanisms by which urushiols initiate the allergic response. Results: Electron microscopy observations of mouse ears exposed to litreol (3-n-pentadecyl-10-enyl-catechol]) showed keratinocytes containing swollen mitochondria with round electron-dense inclusion bodies in the matrix. Biochemical analyses of sub-mitochondrial fractions revealed an inhibitory effect of urushiols on electron flow through the mitochondrial respiratory chain, which requires both the aliphatic and catecholic moieties of these allergens. Moreover, urushiols extracted from poison ivy/oak (mixtures of 3-n-pentadecyl-8,11,13 enyl/3-n-heptadecyl-8,11 enyl catechol) exerted a higher inhibitory effect on mitochondrial respiration than did pentadecyl catechol or litreol, indicating that the higher number of unsaturations in the aliphatic chain, stronger the allergenicity of urushiols. Furthermore, the analysis of radioactive proteins isolated from mitochondria incubated with 3H-litreol, indicated that this urushiol was bound to cytochrome c1. According to the proximity of cytochromes c1 and b, functional evidence indicated the site of electron flow inhibition was within complex III, in between cytochromes bL (cyt b566) and bH (cyt b562). Conclusion: Our data provide functional and molecular evidence indicating that the interruption of the mitochondrial electron transport chain constitutes an important mechanism by which urushiols initiates the allergic response. Thus, mitochondria may constitute a source of cellular targets for generating neoantigens involved in the T-cell mediated allergy induced by urushiols.
  • Thumbnail Image
    Item
  • Thumbnail Image
    Item
    An Update on Host-Pathogen Interplay and Modulation of Immune Responses during Orientia tsutsugamushi Infection
    (2018) Díaz Acevedo, Fabián Esteban; Abarca Villaseca, Katia; Kalergis Parra, Alexis Mikes
  • Thumbnail Image
    Item
  • Thumbnail Image
    Item
    Antibody development for preventing the human respiratory syncytial virus pathology.
    (2020) Soto Ramírez, Jorge Andrés; Gálvez Arriagada, Nicolás Marcelo Salvador; Pacheco, Gaspar A.; Bueno Ramírez, Susan; Kalergis Parra, Alexis Mikes
    Abstract Human respiratory syncytial virus (hRSV) is the most important etiological agent causing hospitalizations associated with respiratory diseases in children under 5 years of age as well as the elderly, newborns and premature children are the most affected populations. This viral infection can be associated with various symptoms, such as fever, coughing, wheezing, and even pneumonia and bronchiolitis. Due to its severe symptoms, the need for mechanical ventilation is not uncommon in clinical practice. Additionally, alterations in the central nervous system -such as seizures, encephalopathy and encephalitis- have been associated with cases of hRSV-infections. Furthermore, the absence of effective vaccines or therapies against hRSV leads to elevated expenditures by the public health system and increased mortality rates for the high-risk population. Along these lines, vaccines and therapies can elicit different responses to this virus. While hRSV vaccine candidates seek to promote an active immune response associated with the achievement of immunological memory, other therapies -such as the administration of antibodies- provide a protective environment, although they do not trigger the activation of the immune system and therefore do not promote an immunological memory. An interesting approach to vaccination is the use of virus-neutralizing antibodies, which inhibit the entry of the pathogen into the host cells, therefore impairing the capacity of the virus to replicate. Currently, the most common molecule targeted for antibody design against hRSV is the F protein of this virus. However, other molecular components of the virus -such as the G or the N hRSV proteins- have also been explored as potential targets for the control of this disease. Currently, palivizumab is the only monoclonal antibody approved for human use. However, studies in humans have shown a protective effect only after the administration of at least 3 to 5 doses, due to the stability of this vaccine. Furthermore, other studies suggest that palivizumab only has an effectiveness close to 50% in high-risk infants. In this work, we will review different strategies addressed for the use of antibodies in a prophylactic or therapeutic context and their ability to prevent the symptoms caused by hRSV infection of the airways, as well as in other tissues such as the CNS.Abstract Human respiratory syncytial virus (hRSV) is the most important etiological agent causing hospitalizations associated with respiratory diseases in children under 5 years of age as well as the elderly, newborns and premature children are the most affected populations. This viral infection can be associated with various symptoms, such as fever, coughing, wheezing, and even pneumonia and bronchiolitis. Due to its severe symptoms, the need for mechanical ventilation is not uncommon in clinical practice. Additionally, alterations in the central nervous system -such as seizures, encephalopathy and encephalitis- have been associated with cases of hRSV-infections. Furthermore, the absence of effective vaccines or therapies against hRSV leads to elevated expenditures by the public health system and increased mortality rates for the high-risk population. Along these lines, vaccines and therapies can elicit different responses to this virus. While hRSV vaccine candidates seek to promote an active immune response associated with the achievement of immunological memory, other therapies -such as the administration of antibodies- provide a protective environment, although they do not trigger the activation of the immune system and therefore do not promote an immunological memory. An interesting approach to vaccination is the use of virus-neutralizing antibodies, which inhibit the entry of the pathogen into the host cells, therefore impairing the capacity of the virus to replicate. Currently, the most common molecule targeted for antibody design against hRSV is the F protein of this virus. However, other molecular components of the virus -such as the G or the N hRSV proteins- have also been explored as potential targets for the control of this disease. Currently, palivizumab is the only monoclonal antibody approved for human use. However, studies in humans have shown a protective effect only after the administration of at least 3 to 5 doses, due to the stability of this vaccine. Furthermore, other studies suggest that palivizumab only has an effectiveness close to 50% in high-risk infants. In this work, we will review different strategies addressed for the use of antibodies in a prophylactic or therapeutic context and their ability to prevent the symptoms caused by hRSV infection of the airways, as well as in other tissues such as the CNS.Abstract Human respiratory syncytial virus (hRSV) is the most important etiological agent causing hospitalizations associated with respiratory diseases in children under 5 years of age as well as the elderly, newborns and premature children are the most affected populations. This viral infection can be associated with various symptoms, such as fever, coughing, wheezing, and even pneumonia and bronchiolitis. Due to its severe symptoms, the need for mechanical ventilation is not uncommon in clinical practice. Additionally, alterations in the central nervous system -such as seizures, encephalopathy and encephalitis- have been associated with cases of hRSV-infections. Furthermore, the absence of effective vaccines or therapies against hRSV leads to elevated expenditures by the public health system and increased mortality rates for the high-risk population. Along these lines, vaccines and therapies can elicit different responses to this virus. While hRSV vaccine candidates seek to promote an active immune response associated with the achievement of immunological memory, other therapies -such as the administration of antibodies- provide a protective environment, although they do not trigger the activation of the immune system and therefore do not promote an immunological memory. An interesting approach to vaccination is the use of virus-neutralizing antibodies, which inhibit the entry of the pathogen into the host cells, therefore impairing the capacity of the virus to replicate. Currently, the most common molecule targeted for antibody design against hRSV is the F protein of this virus. However, other molecular components of the virus -such as the G or the N hRSV proteins- have also been explored as potential targets for the control of this disease. Currently, palivizumab is the only monoclonal antibody approved for human use. However, studies in humans have shown a protective effect only after the administration of at least 3 to 5 doses, due to the stability of this vaccine. Furthermore, other studies suggest that palivizumab only has an effectiveness close to 50% in high-risk infants. In this work, we will review different strategies addressed for the use of antibodies in a prophylactic or therapeutic context and their ability to prevent the symptoms caused by hRSV infection of the airways, as well as in other tissues such as the CNS.Abstract Human respiratory syncytial virus (hRSV) is the most important etiological agent causing hospitalizations associated with respiratory diseases in children under 5 years of age as well as the elderly, newborns and premature children are the most affected populations. This viral infection can be associated with various symptoms, such as fever, coughing, wheezing, and even pneumonia and bronchiolitis. Due to its severe symptoms, the need for mechanical ventilation is not uncommon in clinical practice. Additionally, alterations in the central nervous system -such as seizures, encephalopathy and encephalitis- have been associated with cases of hRSV-infections. Furthermore, the absence of effective vaccines or therapies against hRSV leads to elevated expenditures by the public health system and increased mortality rates for the high-risk population. Along these lines, vaccines and therapies can elicit different responses to this virus. While hRSV vaccine candidates seek to promote an active immune response associated with the achievement of immunological memory, other therapies -such as the administration of antibodies- provide a protective environment, although they do not trigger the activation of the immune system and therefore do not promote an immunological memory. An interesting approach to vaccination is the use of virus-neutralizing antibodies, which inhibit the entry of the pathogen into the host cells, therefore impairing the capacity of the virus to replicate. Currently, the most common molecule targeted for antibody design against hRSV is the F protein of this virus. However, other molecular components of the virus -such as the G or the N hRSV proteins- have also been explored as potential targets for the control of this disease. Currently, palivizumab is the only monoclonal antibody approved for human use. However, studies in humans have shown a protective effect only after the administration of at least 3 to 5 doses, due to the stability of this vaccine. Furthermore, other studies suggest that palivizumab only has an effectiveness close to 50% in high-risk infants. In this work, we will review different strategies addressed for the use of antibodies in a prophylactic or therapeutic context and their ability to prevent the symptoms caused by hRSV infection of the airways, as well as in other tissues such as the CNS.
  • No Thumbnail Available
    Item
  • No Thumbnail Available
    Item